Rosen Law Firm Encourages Vistagen Therapeutics (VTGN) Investors to Take Action Before March 16 Deadline

New York, United States – Rosen Law Firm, a globally recognized investor rights law firm, has issued an urgent reminder to investors who purchased shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) during a specific period to secure legal representation before the important March 16, 2026 deadline in a securities class action lawsuit.

The firm is encouraging affected investors to act quickly if they wish to participate in the lawsuit or seek appointment as a lead plaintiff in the case. This class action lawsuit alleges violations of federal securities laws by Vistagen Therapeutics and certain executives of the company.

According to legal filings, investors who purchased or acquired Vistagen common stock between April 1, 2024 and December 16, 2025 may be eligible to join the lawsuit and potentially recover financial losses. This timeframe is referred to as the “Class Period.”

Overview of the Securities Class Action Against Vistagen Therapeutics

The class action lawsuit filed against Vistagen Therapeutics seeks to represent investors who allegedly suffered losses due to misleading statements and omissions made by the company during the Class Period.

Vistagen Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for anxiety, depression, and other central nervous system disorders. As a publicly traded company on the NASDAQ stock exchange, the firm is required to provide accurate and transparent disclosures to investors.

The lawsuit claims that the company and certain senior executives may have violated federal securities laws by making statements that were materially misleading or by failing to disclose key information to investors. When such information later becomes known, it can lead to significant declines in stock prices and financial losses for shareholders.

Through the class action mechanism, investors who purchased shares during the specified period may be able to collectively pursue compensation for alleged damages.

Important March 16, 2026 Deadline for Lead Plaintiff Applications

A critical aspect of the case is the deadline for investors who wish to serve as a lead plaintiff. According to the notice issued by Rosen Law Firm, investors must file a motion with the court no later than March 16, 2026 if they want to be considered for this role.

The lead plaintiff is typically the investor or group of investors who suffered the largest financial losses and who agree to represent the interests of the entire class of shareholders. The lead plaintiff works closely with the attorneys overseeing the litigation and helps guide the direction of the case.

However, it is important to note that investors do not need to become lead plaintiffs in order to participate in any potential recovery. Even those who choose not to take on this role may still be eligible to receive compensation if the lawsuit results in a settlement or court award.

Who May Be Eligible to Participate in the Lawsuit

Investors may be eligible to participate in the Vistagen securities class action if they meet the following criteria:

• Purchased or otherwise acquired Vistagen Therapeutics common stock
• Shares were purchased between April 1, 2024 and December 16, 2025
• Experienced financial losses related to their investment

The lawsuit seeks to represent all investors who purchased shares during the Class Period and were allegedly impacted by the company’s actions.

Individuals who meet these criteria are encouraged to contact legal counsel to learn more about their rights and options under federal securities laws.

Why Rosen Law Firm Is Encouraging Investors to Secure Counsel

Rosen Law Firm has established a reputation as a leading global investor rights firm specializing in securities class actions and shareholder litigation. The firm has successfully represented investors in high-profile cases and has achieved significant settlements on behalf of shareholders worldwide.

Legal experts emphasize that selecting experienced counsel can play an important role in complex securities litigation. Firms with established track records and resources are often better positioned to pursue claims against publicly traded companies and defend investors’ rights.

Rosen Law Firm advises investors to carefully evaluate legal representation before participating in any securities class action.

Background on Vistagen Therapeutics

Vistagen Therapeutics is a biotechnology company that focuses on developing innovative therapies for mental health disorders and neurological conditions. The company’s research primarily targets anxiety-related conditions, depression, and other central nervous system disorders.

The company’s pipeline includes several investigational treatments designed to address unmet medical needs in mental health care. These treatments are currently undergoing clinical research and development.

Biopharmaceutical companies like Vistagen often rely heavily on investor funding to support research, clinical trials, and regulatory approvals. Because of this reliance, accurate financial disclosures and transparent communications with shareholders are essential.

When investors believe that important information has been withheld or misrepresented, they may seek legal remedies through securities litigation.

Understanding Securities Class Action Lawsuits

Securities class action lawsuits are a common legal mechanism used by investors who believe they were harmed by misleading or fraudulent statements made by publicly traded companies.

These lawsuits typically arise when:

• A company issues misleading financial statements
• Executives make inaccurate public statements about business operations
• Important risks or problems are not disclosed to investors
• Stock prices drop significantly after new information becomes public

By combining claims from many investors into a single lawsuit, the class action structure allows individuals to pursue legal action that might otherwise be too costly to bring on their own.

If successful, the case could result in financial compensation for affected shareholders.

Role and Responsibilities of the Lead Plaintiff

The lead plaintiff serves an important function in securities class action litigation. This individual or group of investors acts as the primary representative for all class members.

Responsibilities of the lead plaintiff typically include:

• Working with attorneys to oversee litigation strategy
• Reviewing legal filings and court documents
• Representing the interests of the entire class of investors
• Participating in settlement discussions if applicable

Courts generally appoint the investor with the largest financial interest in the case, provided they can adequately represent the class.

What Investors Should Do Next

Investors who purchased Vistagen Therapeutics shares during the Class Period should carefully review their investment records to determine whether they may qualify to participate in the lawsuit.

Those interested in becoming lead plaintiffs must submit the appropriate motion to the court before the March 16, 2026 deadline.

Even if investors do not wish to serve as lead plaintiffs, they may still remain part of the class and benefit from any potential recovery.

Legal experts recommend consulting experienced securities attorneys who can evaluate the situation and provide guidance on next steps.

Growing Attention Around Investor Rights and Corporate Accountability

The Vistagen case reflects a broader trend of increased scrutiny of publicly traded companies and their communications with investors.

Regulators, investors, and legal professionals continue to emphasize transparency, accountability, and accurate reporting in the financial markets.

When companies fail to meet these standards, class action lawsuits can serve as an important mechanism for protecting investors and maintaining trust in the capital markets.

The outcome of this lawsuit could potentially have implications not only for Vistagen Therapeutics but also for the broader biotechnology and pharmaceutical industries.

Conclusion

The securities class action lawsuit involving Vistagen Therapeutics highlights the importance of investor awareness and timely action.

With the March 16, 2026 deadline approaching, investors who purchased Vistagen shares between April 1, 2024 and December 16, 2025 should consider reviewing their legal options.

By seeking qualified legal counsel and understanding their rights, investors can determine whether they wish to participate in the class action or pursue the role of lead plaintiff.

As the legal proceedings move forward, the case will continue to draw attention from investors, legal experts, and the broader financial community.

#VTGN #VistagenTherapeutics #SecuritiesClassAction #InvestorAlert #SlimScan #GrowthStocks #CANSLIM